Q1 2026 Atea Pharmaceuticals Inc Earnings Call Transcript

May 12, 2026 / 08:30 PM GMT

Release Date Price: $5.5 (+1.66%)

Transcript 10-Q8-K

Key Points

Positve

Atea Pharmaceuticals Inc (AVIR) has completed patient enrollment for its North American trial with over 880 patients, representing diverse genotypes and demographics.
The company is financially strong with $256 million in cash and marketable securities, ensuring the completion of its Phase 3 HCV program and advancement of the HEV development program.
Atea's regimen for hepatitis C shows a potentially best-in-class profile with high efficacy, short treatment duration, and low risk for drug-drug interactions.
The company is strategically expanding its antiviral pipeline to address unmet medical needs for immunocompromised patients with chronic hepatitis E infection.
Atea's commercial strategy includes a capital-efficient launch with a focused sales force, leveraging a concentrated prescriber base for rapid market penetration.

Negative

The global incidence of hepatitis C infections continues to rise, outpacing the number of patients being treated, highlighting a significant healthcare challenge.
Most countries, including the U.S., are not on track to meet the World Health Organization's goal of HCV elimination by 2030.
The company faces competition from established regimens like ICLUSA and MAVIRET, which have significant market presence.
Atea's financial results show increased R&D expenses due to external spending on clinical development, which could impact profitability.
The success of Atea's commercial launch is contingent on achieving favorable payer access and overcoming potential hurdles in integrating into test-and-treat initiatives.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AVIR.OQ - Atea Pharmaceuticals Inc
Q1 2026 Atea Pharmaceuticals Inc Earnings Call
May 12, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, thank you for standing by, and welcome to Atelia Thermal Pharmaceuticals' first quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. If you should require operator assistance during the conference, please press *0 on your telephone keypad. I will now turn it over to the ATIA's management team. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Hi, thank you, operator. Good afternoon, everyone, and welcome to Attea

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.